Last reviewed · How we verify
Artemether-lumefantrine: P. falciparum
Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.
Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway. Used for Uncomplicated Plasmodium falciparum malaria.
At a glance
| Generic name | Artemether-lumefantrine: P. falciparum |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Antimalarial |
| Target | Mitochondrial electron transport chain, Heme detoxification pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Artemether-lumefantrine is a combination therapy used to treat uncomplicated Plasmodium falciparum malaria. Artemether is a potent inhibitor of the parasite's mitochondrial electron transport chain, while lumefantrine is a potent inhibitor of the parasite's heme detoxification pathway.
Approved indications
- Uncomplicated Plasmodium falciparum malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (PHASE3)
- Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum (PHASE1)
- Safety of Antimalarials in the FIRst trimEster (PHASE3)
- Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield (NA)
- Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria (PHASE1)
- A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) (PHASE1)
- Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali (PHASE2)
- Short Course Radical Cure of P. Vivax Malaria in Nepal (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: